Hospitalized patients with opioid use disorder (OUD) often face significant hurdles during acute medical care. These individuals frequently experience patient-directed discharge (PDD) and incomplete antibiotic regimens. Consequently, clinicians must evaluate effective Opioid withdrawal management strategies to ensure successful treatment of serious infections like bacteremia. A recent retrospective study at Temple University Hospital highlights the critical differences between two common approaches: Medications for Opioid Use Disorder (MOUD) and high-dose opioid agonist therapy (HDOAT).

The study analyzed 383 patient encounters involving OUD and bacteremia between 2020 and 2022. Researchers compared patients receiving MOUD, such as methadone and buprenorphine, against those receiving HDOAT alone. In this context, HDOAT involved full agonists like oxycodone or hydromorphone at doses reaching up to 2,070 Morphine Milligram Equivalents (MMEs) per day. Surprisingly, despite the high doses used in the HDOAT group, the clinical outcomes favored the MOUD group significantly.

Notably, MOUD was associated with a much higher rate of antibiotic completion. Specifically, 35.0% of patients in the MOUD group finished their full course, compared to only 23.3% in the HDOAT group. Furthermore, MOUD significantly reduced the risk of patient-directed discharge. These findings suggest that stabilizing the underlying addiction with evidence-based medications is more effective than simply masking withdrawal symptoms with high-dose full agonists. Therefore, clinicians should prioritize the initiation of methadone or buprenorphine over traditional opioid-based comfort measures.

Opioid Withdrawal Management Strategies: Improving Survival

In addition to antibiotic adherence, the study observed a trend toward lower one-year mortality in the MOUD group. Although the differences in short-term readmission rates were less pronounced, the long-term benefit of stabilizing OUD during a medical crisis remains clear. Moreover, managing bacteremia requires a stable, long-term therapeutic environment because these infections necessitate weeks of antimicrobial therapy. Integrating addiction specialists into the care of patients with injection-related infections can bridge the gap between acute medicine and long-term recovery.

Frequently Asked Questions

What is the difference between MOUD and HDOAT?

MOUD involves FDA-approved medications like buprenorphine or methadone specifically for long-term recovery. In contrast, HDOAT refers to using high doses of full opioid agonists (e.g., oxycodone) primarily to manage acute withdrawal symptoms without the stabilization benefits of MOUD.

Why does MOUD improve antibiotic completion?

MOUD effectively reduces cravings and stabilizes the patient's neurological state. This stabilization allows the patient to remain in the hospital for the duration of the antibiotic course, reducing the likelihood of leaving against medical advice.

Can HDOAT be used as a bridge to MOUD?

While HDOAT may provide temporary relief, the study suggests it is less effective than MOUD at improving clinical outcomes. Most experts recommend transitioning to MOUD as early as possible during the hospital stay.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Handy S et al. Comparative outcomes of opioid withdrawal management strategy in patients with injection-related bacteremia. J Addict Dis. 2026 Jun 15. doi: 10.1080/10550887.2026.2685063. PMID: 42290474.

Lewis S et al. Patients with serious injection drug use-related infections who experience patient-directed discharges on oral antibiotics have high rates of antibiotic adherence but require multidisciplinary outpatient support. Open Forum Infect Dis. 2022;9(2):ofab633.

Alrawashdeh M et al. Epidemiology, Outcomes, and Trends of Patients With Sepsis and Opioid-Related Hospitalizations in U.S. Hospitals. Crit Care Med. 2021;49(12):2102-2111.